Wordt geladen...
Does it help that efficacy has been proven once we start discussing (added) benefit?
Since the introduction of benefit assessment to support reimbursement decisions in Germany there seems to be the impression that totally distinct methodology and strategies for decision making would apply in the field of drug licensing and reimbursement. In this article, the position is held that, w...
Bewaard in:
| Gepubliceerd in: | Biom J |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
John Wiley and Sons Inc.
2015
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4758384/ https://ncbi.nlm.nih.gov/pubmed/26140608 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/bimj.201400017 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|